Thromboembolic Event clinical trials

Explore recruiting thromboembolic event clinical trials.

Recruiting thromboembolic event studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Thromboembolic Event trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Master Protocol for a Phase 2 Randomized, Double-blind, Placebo-controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies against Factor XI for Prevention of Venous Thromboembolism in Patients with a Peripherally Inserted Central Catheter (ROXI-CATH).

Spain, Romania, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

Screening for occult malignancy using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)

Greece, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism after Elective, Unilateral, Total Knee Arthroplasty

Lithuania, Latvia, Poland, Hungary, Bulgaria, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)

Bulgaria, Poland, Hungary, Latvia, Lithuania

Therapeutic exploratory (Phase II) EU CTIS Study details

(21751) First-in-human single dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 3018250 in healthy men in a randomized, placebo-controlled, single-blind, group-comparison design

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Thromboembolic Event trials by city

Thromboembolic Event in Toronto Thromboembolic Event in Vancouver Thromboembolic Event in Montreal Thromboembolic Event in Calgary Thromboembolic Event in Edmonton Thromboembolic Event in Ottawa Thromboembolic Event in Winnipeg Thromboembolic Event in Quebec City Thromboembolic Event in Hamilton Thromboembolic Event in Kitchener Thromboembolic Event in London Thromboembolic Event in Halifax Thromboembolic Event in New York Thromboembolic Event in Los Angeles Thromboembolic Event in Chicago Thromboembolic Event in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease